Product category:
Clinical chemistry analysis
News Release from: Ipsogen | Subject: Jak2
Edited by the Laboratorytalk Editorial
Team on 04 December 2007
Pilot study on Jak2 cancer biomarker
Ipsogen has entered into a pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research
Ipsogen will provide AstraZeneca with Jak2-based products for initial evaluation Ipsogen will conduct quantitative analysis in its Marseille laboratories on samples provided by AstraZeneca
This article was originally published on Laboratorytalk on 22 Nov 2007 at 8.00am (UK)
Related stories
Accurate quantification of Jak2 V617F mutation
Ipsogen has developed a range of molecular assays based on mutations in the Jak2 gene, to which the company has worldwide exclusive intellectual property rights
The study will help determine the viability of a test which could potentially be utilised by AstraZeneca in future clinical trials.
Ipsogen is the exclusive worldwide licensee of the intellectual property on Jak2 V617F mutation discovered by the Inserm team of Vainchenker at Institut Gustave Roussy, Paris.
The company has developed a comprehensive suite of products and services in order to assist pharmaceutical companies in the development of Jak2 inhibitors in myeloproliferative disorders.
Ipsogen says it intends to provide the best diagnostic tools in order to reduce the number of patients included into clinical trials, reduce the time to results and provide the most adapted diagnostic solution to personalize drug prescription.
"We are pleased to start up our Jak2 Pharma programme with AstraZeneca a major pharmaceutical company with an outstanding vision in personalized medicine.
"We are confident that our Jak2 based diagnostic products and clinical services can satisfy pharmaceutical companies and can improve the pace of development of therapeutic solution for cancer patients" said Vincent Fert, president and CEO of Ipsogen.
• Ipsogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
